Scholar Rock

Scholar Rock works on 2 rare diseases tracked on Trial Friend, including Facioscapulohumeral Muscular Dystrophy, Spinal Muscular Atrophy, with 3 recruiting clinical trials.

Scholar Rock is a Cambridge, Massachusetts biotech that spent roughly a decade chasing a target the rest of the industry had largely given up on, and in September 2026 became the first company to make it work. The company was built on research from Harvard Medical School and Boston Children's Hospital into the TGF-beta superfamily, a group of proteins that regulate how tissue grows and repairs itself. Its central insight is a matter of timing. Most of these growth factors are produced in an inactive precursor form and have to be switched on before they do anything, and Scholar Rock designs antibodies that grab the precursor rather than the finished protein. Targeting the switch instead of the signal is what allows its drugs to hit one growth factor without disturbing its close relatives, which is where earlier attempts in this field ran aground. The company trades on Nasdaq under SRRK.

The proof is ISEMBYLD (apitegromab), approved by the FDA on September 11, 2026 for spinal muscular atrophy in adults and children 2 and older who are already receiving an SMN2-targeted treatment. It is the first muscle-targeted treatment for SMA and the company's first approved product. Every SMA drug before it, Spinraza, Zolgensma and Evrysdi, worked on the genetic root of the disease by protecting motor neurons, and none of them addressed muscle that had already wasted away. Apitegromab blocks myostatin, the body's natural brake on muscle growth, which is why it is given alongside an existing SMN therapy rather than in place of one. In the Phase 3 SAPPHIRE trial, patients aged 2 to 12 on the recommended dose gained motor function over a year while those on an SMN drug alone continued to lose it. Drug companies have been trying to drug myostatin since the early 2000s across muscular dystrophy, cachexia and age-related muscle loss, and the record until this approval was a long run of failures.

The same platform is aimed at several other areas. Apitegromab is also being studied in cardiometabolic disease, where preserving muscle during rapid weight loss on GLP-1 drugs is an open question, and the pipeline includes programs in immuno-oncology targeting TGF-beta 1 in solid tumors, plus earlier work in fibrosis and anemia. For SMA families, the practical significance is narrower and clearer: after a decade in which every new option worked the same way, there is now a second mechanism to add on top.